| ||||
| Prostate brachytherapy (radioactive seed implants), anti-angiogenesis research, Translation laboratory research Dr. Dicker is Professor and Interim Chairman of Radiation Oncology and Director of the Division of Experimental Radiation oncology in the Department of Radiation oncology at Thomas Jefferson University. He also is the Lead Physician for the Prostate Brachytherapy Program at Thomas Jefferson University Hospital. Dr. Dicker graduated from Columbia College and received his MD and PhD from Cornell University Medical College. He completed an internship in Surgery at Lenox Hill Hospital and completed his residency in Department of Radiation oncology at the Memorial Sloan-Kettering Cancer Center. His laboratory research funded by the National Cancer Institute involves studying the role of the Epidermal Growth Factor Receptor (EGFR) and tumor microenvironment in solid tumors. His research evaluates radiosensitization by EGFR blockade through an understanding of survival signals derived from extracellular matrix (ECM). Dr. Dicker’s other research effort builds on the use of zebrafish as a model organism to study molecular mechanisms of damage by radiation and chemotherapy. Dr. Dicker’s laboratory program uses this model organism in conjunctional with nanotechnology drugs (nanoparticles) to identify novel radiation protectors/mitigators. In the field of prostate cancer, over the past decade, Dr. Dicker and his colleagues have contributed a number of original papers in the field of prostate brachytherapy. These papers have focused on the definition and evaluation of post-implant dosimetry and its effect on the actual dose to the prostate, urethra and rectum. More recently, this group has focused on quality life issues after prostate brachytherapy and predictive factors that will help the guide the physician and individualize the appropriate therapy for treatment of prostate cancer for the respective patient. Dr. Dicker and his colleagues have recently published a comprehensive text, “Basic and Advanced Techniques in Prostate Brachytherapy”, Frances & Taylor, 2005 that reviews in detail all aspects of prostate cancer and brachytherapy, with particular attention to practical techniques and issues that can be incorporated into daily practice. Dr. Dicker serves as the Vice Chair for Translational Research and Chair of the Translational Research Committee in the Radiation Therapy oncology Group (RTOG) a National Cancer Institute sponsored cooperative group. In addition, he is the principal investigator on a number of clinical developmental therapeutic protocols involving novel signal transduction agents at Thomas Jefferson University. Dr. Dicker is Vice Chair for Radiation Biology and Cancer Committee for ASTRO and also serves as a member of the Corporate Relations Committee. Dr. Dicker is a board certified radiation oncologist. Among other honors, he has received an American Cancer Society Fellowship and an ASTRO/ESTRO Travel Grant. If you have any questions or would like to refer a patient to Dr. Dicker please contact him at: Department of Radiation oncology Keywords: | ||||
| Selected Publications Woodward WA, Wachsberger P, Burd R, Dicker AP. Effects of androgen suppression and radiation on prostate cancer suggest role for angiogenesis blockade. Prostate Cancer Prostatic Dis 2005 Jan 11;. ( Abstract ) McAleer MF, Davidson C, Davidson WR, Yentzer B, Farber SA, Rodeck U, Dicker AP. Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys 2005 Jan 1;61(1):10-3.. ( Abstract ) Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesi signaling pathways. Hematol Oncol Clin North Am 2004 Oct;18(5):1039-57, viii. ( Abstract ) McElveen TL, Waterman FM, Kim H, Dicker AP. Factors predicting for urinary incontinence after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004 Aug 1;59(5):1395-404. ( Abstract ) Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker fo evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004 Jun 1;10(11):3927-33. ( Abstract ) Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ. Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res 2004 Jun 1;10(11):3897-907. ( Abstract ) Lanza-Jacoby S, Dicker AP, Miller S, Rosato FE, Flynn JT, Lavorgna SN, Burd R. Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther 2004 Apr;3(4):417-24.. ( Abstract ) Patel AB, Waterman FM, Dicker AP. A detailed examination of the difference between planned and treate margins in 125I permanent prostate brachytherapy. Brachytherapy 2003;2(4):223-8. ( Abstract ) Forsberg F, Ro RJ, Potoczek M, Liu JB, Merritt CR, James KM, Dicker AP, Nazarian LN. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 2004 Apr;42(1-9):325-30. ( Abstract ) Dicker AP, Rodeck U. Targeting the EGFR in neoplasia--more questions than answers. Int J Radiat Oncol Biol Phys 2004 Mar 1;58(3):899-902. ( Abstract ) Waterman FM, Dicker AP. Is it necessary to eliminate the posterior dose margin in prostat brachytherapy to achieve an acceptably low risk of late rectal morbidity. Int J Radiat Oncol Biol Phys 2003 Sep 1;57(1):293-9. ( Abstract ) Lin CC, Kenyon L, Hyslop T, Hammond E, Andrews DW, Curran WJ Jr, Dicker AP. Cyclooxygenase-2 (COX-2) expression in human meningioma as a function o tumor grade. Am J Clin Oncol 2003 Aug;26(4):S98-102. ( Abstract ) Bloomer CW, Kenyon L, Hammond E, Hyslop T, Andrews DW, Curran WJ, Dicker AP. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR expression in human pituitary macroadenomas. Am J Clin Oncol 2003 Aug;26(4):S75-80. ( Abstract ) Dicker AP. COX-2 inhibitors and cancer therapeutics: potential roles for inhibitor of COX-2 in combination with cytotoxic therapy: reports from a symposiu held in conjunction with the Radiation Therapy Oncology Group June 200 Meeting. Am J Clin Oncol 2003 Aug;26(4):S46-7. ( Abstract ) Dicker AP, Williams TL, Iliakis G, Grant DS. Targeting angiogenic processes by combination low-dose paclitaxel an radiation therapy. Am J Clin Oncol 2003 Jun;26(3):e45-53. ( Abstract ) Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis o vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003 Jun;9(6):1957-71. ( Abstract ) Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003 Mar 10;104(1):121-9.. ( Abstract ) Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003 Feb 1;55(2):342-53. ( Abstract ) Dicker AP. The safety and tolerability of low-dose irradiation for the management o gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 2003 Jan;4(1):30-6. ( Abstract ) Waterman FM, Dicker AP. Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy can implant quality be predicted on day 0. Int J Radiat Oncol Biol Phys 2002 Jul 1;53(3):610-21. ( Abstract ) Forsberg F, Dicker AP, Thakur ML, Rawool NM, Liu JB, Shi WT, Nazarian LN. Comparing contrast-enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenograft model: preliminary results. Ultrasound Med Biol 2002 Apr;28(4):445-51.. ( Abstract ) Chen CT, Waterman FM, Valicenti RK, Gomella LG, Strup SE, Dicker AP. Dosimetric analysis of urinary morbidity following prostate brachytherap (125I vs. 103Pd) combined with external beam radiation therapy. Int J Cancer 2001;96 Suppl:83-8. ( Abstract ) Kaminski JM, Kaminski RJ, Dicker AP, Urbain JL. Defining a future role for radiogenic therapy. Cancer Treat Rev 2001 Oct;27(5):289-94. ( Abstract ) Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by prostate brachytherapy? A analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys 2001 Dec 1;51(5):1196-9. ( Abstract ) Gaffney DK, Holden J, Zempolich K, Murphy KJ, Dicker AP, Dodson M. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol 2001 Oct;24(5):443-6.. ( Abstract ) Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizin radiation. Am J Clin Oncol 2001 Oct;24(5):438-42. ( Abstract ) Chen CT, Valicenti RK, Lu J, Derose T, Dicker AP, Strup SE, Mulholland SG, Hirsch IH, McGinnis DE, Gomella LG. Does hormonal therapy influence sexual function in men receiving 3 conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2001 Jul 1;50(3):591-5. ( Abstract ) Cvetkovic D, Movsas B, Dicker AP, Hanlon AL, Greenberg RE, Chapman JD, Hanks GE, Tricoli JV. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001 Apr;57(4):821-5.. ( Abstract ) Dicker AP, Lin CC, Leeper DB, Waterman FM. Isotope selection for permanent prostate implants? An evaluation of 103P versus 125I based on radiobiological effectiveness and dosimetry. Semin Urol Oncol 2000 May;18(2):152-9. ( Abstract ) Waterman FM, Dicker AP. The impact of postimplant edema on the urethral dose in prostat brachytherapy. Int J Radiat Oncol Biol Phys 2000 Jun 1;47(3):661-4. ( Abstract ) Dicker AP, Figura AT, Waterman FM, Valicenti RK, Strup SE, Gomella LG. Is there a role for antibiotic prophylaxis in transperineal interstitia permanent prostate brachytherapy. Tech Urol 2000 Jun;6(2):104-8. ( Abstract ) Maguire PD, Waterman FM, Dicker AP. Can the cost of permanent prostate implants be reduced? An argument for peripheral loading with higher strength seeds. Tech Urol 2000 Jun;6(2):85-8.. ( Abstract ) Waterman FM, Dicker AP. Determination of the urethral dose in prostate brachytherapy when th urethra cannot be visualized in the postimplant CT scan. Med Phys 2000 Mar;27(3):448-51. ( Abstract ) | ||||
Maintained by the Informatics Shared
Resources at the Kimmel Cancer Center at Jefferson
Copyright© Thomas Jefferson University. All Rights Reserved.
The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement